REGN7508 in Adult Participants for Prevention of Cancer-Associated Thrombosis
ConditionCancer-Associated Thrombosis (CAT)
Trial statusRecruiting
Trial phasePhase 3
Trial typeInterventional
Biological sexAll
Age18+
SponsorRegeneron Pharmaceuticals
About this trial
This study is researching an experimental drug called REGN7508 (called "study drug"). The study is focused on the prevention of Cancer-Associated Thrombosis (CAT) in participants.
The aim of the study is to see how effective the study drug is in preventing blood clots in participants with solid tumors who are currently receiving anticancer treatment or planning to start anticancer treatment within a month of being assigned to a study treatment, or recovering from surgery, and how the study drug compares to placebo for CAT.
The study is looking at several other research questions, including:
* What side effects may happen from taking the study drug * How much study drug is in the blood at different times * Whether the body makes antibodies against the study drug (which could make the study drug less effective or could lead to side effects)
Eligibility criteria
Qualifiers
Has a histologically confirmed diagnosis of malignant solid tumors which are locally advanced or metastatic as described in the protocol
Has a Khorana thromboembolic risk score ≥2 during screening period or harbors a somatic documented tumor genetic variant known to be associated with a similar increased risk of VTE as described in the protocol
Has an Eastern Cooperative Oncology Group (ECOG) Performance Status 0 to 2 at the time of screening and day 1 prior to the first dose of study intervention
Disqualifiers
Has known bleeding conditions (eg, Hemophilia A or B, von Willebrand's disease), hemorrhagic tumor sites, or other conditions with a high risk for bleeding (eg, hepatic disease associated with coagulopathy)
Has a cancer diagnosis consisting solely of basal cell or squamous cell skin carcinoma
Has a primary brain tumor or brain metastases as described in the protocol
Has proximal lower extremity DVT locally detected by Compression Ultrasound (CUS) during screening period
Trial design
Treatments tested in this trial
- REGN7508
- Placebo
Treatment groups
1,120 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov